Market Spotlight: Acne
|出版日期||內容資訊||英文 53 Pages
|關注市場分析:痤瘡 Market Spotlight: Acne|
|出版日期: 2019年11月27日||內容資訊: 英文 53 Pages||
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 624 million prevalent cases of acne worldwide, and forecasts that number to increase to 683 million prevalent cases by
2026. Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.
The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with two drugs in the NDA/BLA phase.
Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
High-impact upcoming events for drugs in the acne space comprise topline Phase II trial results for FCD105, topline Phase III trial results for TWIN, and estimated PDUFA dates for Arazlo and Winlevi/Breezula.
The overall likelihood of approval of a Phase I dermatology-general asset is 24.7%, and the average probability a drug advances from Phase III is 75.8%. Drugs, on average, take 7.8 years from Phase I to approval, compared to 7.7 years in the overall dermatology space.
There have been 21 licensing and asset acquisition deals involving acne drugs during 2014-19. The largest deal was the $650m agreement in 2018 between Almirall and Allergan for the acquisition of a portfolio of five products from Allergan's Medical Dermatology unit in the US, which comprises of mature and growth brands Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide), and Seysara (sarecycline).
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III-IV, and 48% in Phase I-II.
The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
GlaxoSmithKline leads industry sponsors with by far the highest number of clinical trials for acne, followed by Allergan.
9 Topical therapy
9 Systemic therapy
10 Physical treatments
26 ANT-1207 for Acne (June 25, 2019)
27 VB 1953 for Acne (May 13, 2019)
28 VB 1953 for Acne (May 13, 2019)
30 Winlevi / Breezula for Acne (March 26, 2019)
32 Aklief for Acne (February 22, 2019)
34 Amzeeq for Acne (September 11, 2018)
36 Winlevi / Breezula for Acne (July 10, 2018)
40 Foamix Earns First Approval For Topical Minocycline With Amzeeq
40 FDA Approves Aklief Cream for Acne Treatment
40 Cassiopea Submits Acne Drug With New Mechanism Of Action
40 Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
41 Foamix Submits First Topical Minocycline For Acne
47 Sponsors by status
48 Sponsors by phase
50 Prescription information